Kiromic BioPharma, Inc. (KRBP)
After hours:
| Previous close | 0.4840 |
| Open | 0.5041 |
| Bid | 0.4999 x 3000 |
| Ask | 0.4711 x 1100 |
| Day's range | 0.3600 - 0.5123 |
| 52-week range | 0.2300 - 9.4500 |
| Volume | |
| Avg. volume | 1,034,509 |
| Market cap | 5.641M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Kiromic BioPharma Pipeline to Prioritize a New Gamma Delta T-cell Product Candidate
HOUSTON, June 21, 2022--Kiromic BioPharma, Inc. (NASDAQ: KRBP), a clinical-stage biotherapeutics company using its proprietary DIAMOND AI® (artificial intelligence) and data mining platform to discover and develop cell therapies with a focus on immuno-oncology, announces a strategic pipeline shift to prioritize its allogeneic, non-engineered off-the-shelf product candidate, Deltacel/KB-GDT™.
- Business Wire
Kiromic BioPharma Significantly Expands Gamma Delta T cell Product Pipeline with New Sponsored Research Agreement
HOUSTON, June 07, 2022--Kiromic BioPharma Significantly Expands Gamma Delta T cell Product Pipeline with New Sponsored Research Agreement
- Business Wire
Kiromic BioPharma Reports First Quarter 2022 Financial Results and Recent Corporate Highlights
HOUSTON, May 13, 2022--Kiromic BioPharma, Inc. (NASDAQ: KRBP) ("Kiromic" or the "Company"), a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence (AI) and data mining platform to discover and develop cell and gene therapies with a therapeutic focus on immuno-oncology, today announces financial results for the first quarter ended March 31, 2022.
